Editor's Corner

Coming off of another successful gathering of BIO, it was interesting to see the heightened -- delirious might be a better word -- interest in biotech by economic development groups from around the world. Biotech is the hottest business in the development world and they pulled out all the stops to woo companies at the gathering in Philadelphia. The host city even pulled off a top ranking in a list of bioclusters put together by the Milken Institute. Their numbers were notoriously padded, of course, in this case by pooling general healthcare employment with biotech. But it's a sign of the luster surrounding biotech that development officials are willing to try so hard to please the industry. Can Chicago top that act next year? We'll see next April. - John Carroll

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.